United Kingdom· GB-APID-41345111000001103
Xenpozyme 20mg powder for concentrate for solution for infusion vials
A olipudase alfa product containing olipudase alfa, registered in United Kingdom by Sanofi. The same ATC class is registered in 14 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Olipudase alfa is registered in 14 of 19 countries.
Countries holding a registration under ATC A16AB25 (olipudase alfa), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 9 of them publish a price we can compare per daily dose
Olipudase alfa · ATC A16AB25
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Olipudase alfa
- Manufacturer
- Sanofi
- Country
- United Kingdom (GB)
- ATC code
- A16AB25
- ATC class
- Olipudase alfa
- Defined daily dose
- 15 mg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 2
- gtin5000283663157
- gtin5000283663058
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Olipudase alfa in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaXENPOZYMESanofi B.V., Amsterdam
- SwitzerlandXenpozyme 20 mg, poudre pour solution à diluer pour perfusionSanofi-Aventis (Suisse) SA
- FinlandXenpozymeSanofi B.V.
- IrelandXenpozyme 20 mg powder for concentrate for solution for infusionSanofi B.V.
- IcelandXenpozymeGenzyme Europe B.V.
- NorwayXenpozymeSanofi B.V.
- PolandXenpozymeSanofi B.V.
- BelgiumXenpozyme 20 mgSanofi
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Xenpozyme
- Liechtenstein · Xenpozyme
- Norway · Xenpozyme
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/63596b2e-78a0-4f30-8781-3bd973018564 GET /v1/drugs/63596b2e-78a0-4f30-8781-3bd973018564?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "41345111000001103",
"desc": "Xenpozyme 20mg powder for concentrate for solution for infusion vials (Sanofi)",
"form": "Powder for solution for infusion",
"vpid": "41346111000001109",
"source": "dmd",
"vtm_id": "41345911000001100",
"strength": "20 mg",
"substance": "Olipudase alfa",
"ingredient": "Olipudase alfa",
"supplier_code": "9190711000001101"
}See everything about olipudase alfa.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.